PELOAcademy|Compatibility of hiPSC-derived cardiomyocytes in cardiac safety assessment of drugsafety (Webinar | Online)
8. Oktober 2024
Webinar
presented by Dr. Jieun An, Nexel Co., Ltd., Republic of Korea Cardiac toxicity is a major cause of compound attrition during drug development as well as for the withdrawal of drugs already on the market. Although ICH S7B guideline has successfully reduced hERG-related risk issues, concerns remain regarding the accuracy of the assay, as hERG blockade does not always correlate with QT prolongation in patients. With recent advances in stem cell technology, it is now possible to generate human inducedWeiterlesen